Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference
CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; 'Cullinan'), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference, being held in New York on February 5 and 6, 2025.
The fireside chat is scheduled for Wednesday, February 5, 2025, at 9:30 a.m. ET. A webcast of the fireside chat will be available under the Events and Presentations section of the Company's investor relations website at https://cullinantherapeutics.com/events-and-presentations/.
About Cullinan TherapeuticsCullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company dedicated to creating new standards of care for patients. Cullinan has strategically built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both autoimmune diseases and cancer. Cullinan's portfolio encompasses a wide range of modalities, each with the potential to be best and/or first in class. Anchored in a deep understanding of oncology, immunology, and translational medicine, we create differentiated ideas, identify the most appropriate targets, and select the optimal modality to develop transformative therapeutics across a wide variety of autoimmune and cancer indications. We push conventional boundaries from candidate selection to differentiated therapeutic, applying rigorous go/no go criteria at each stage of development to fast-track only the most promising molecules to the clinic and, ultimately, commercialization. With deep scientific expertise, our teams exercise creativity and urgency to deliver on our promise to bring new therapeutic solutions to patients. Learn more about Cullinan at https://cullinantherapeutics.com/, and follow us on LinkedIn and X.
Contacts:
Investor RelationsNick Smith+1 401.241.3516nsmith@cullinantx.com
MediaRose Weldon+1 215.801.7644rweldon@cullinantx.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Epoch Times
an hour ago
- Epoch Times
Wall Street Review: S&P 500 Breaks 6,000 in Broad Market Rally
The rally in U.S. stocks continued to broaden this week, driven by a resilient labor market and easing trade tensions between the United States and China. For the first time since it reached an all-time high in February, the S&P 500 Index retook the 6,000 mark on June 6 and closed up 1.5 percent for the week. The Dow Jones Industrial Average gained 1.17 percent to finish at 42,746. The Nasdaq rose by 2.18 percent to 19,529, while the Russell 2000 rallied 3.19 percent.
Yahoo
2 hours ago
- Yahoo
Is CoreWeave Stock a Buy Now?
New AI stock CoreWeave had its initial public offering in March 2025. High demand for AI computing power led to CoreWeave's first-quarter sales soaring more than 400% year over year. The company anticipates sustained revenue growth, but CoreWeave faces financial risks, including operating at a loss. 10 stocks we like better than CoreWeave › Investing in today's stock market can be tricky given the volatile macroeconomic climate, fueled by the Trump administration's ever-shifting tariff policies. But the artificial intelligence sector remains a robust investment opportunity as organizations around the world race to build artificial intelligence (AI) capabilities. Consequently, AI stocks provide the potential for great gains. One example is CoreWeave (NASDAQ: CRWV). The company went public in March at $40 per share. Since then, CoreWeave stock soared to a 52-week high of $166.63 in June. This hot stock remains more than triple its IPO price at the time of this writing. Can it go higher? Evaluating whether now is the time to grab CoreWeave shares requires digging into the company and unpacking its potential as a good investment for the long haul. CoreWeave delivers cloud computing infrastructure to businesses hungry for more computing capacity for their AI systems. The company operates over 30 data centers housing servers and other hardware used by customers to train their AI and develop inference, which is an AI's ability to apply what it learned in training to real-world situations. AI juggernauts such as Microsoft, IBM, and OpenAI, the owner of ChatGPT, are among its roster of customers. The insatiable appetite for AI computing power propelled CoreWeave's business. The company's first-quarter revenue rose a whopping 420% year over year to $981.6 million. Sales growth shows no sign of slowing down. CoreWeave expects Q2 revenue to reach about $1.1 billion. That would represent a strong year-over-year increase of nearly 170% from the prior year's $395 million. The company signs long-term, committed contracts, and as a result, it has visibility into its future revenue potential. At the end of Q1, CoreWeave had amassed a revenue backlog of $25.9 billion, up 63% year over year thanks to a deal with OpenAI. The company forecasts 2025 full-year revenue to come in between $4.9 billion and $5.1 billion, a substantial jump up from 2024's $1.9 billion. Although CoreWeave has enjoyed massive sales success, there are some potential pitfalls with the company. For starters, it isn't profitable. Its Q1 operating expenses totaled $1 billion compared to revenue of $981.6 million, resulting in an operating loss of $27.5 million. Even worse, its costs are accelerating faster than sales, which means the company is moving further away from reaching profitability. CoreWeave's $1 billion in operating expenses represented a 487% increase over the prior year, eclipsing its 420% year-over-year revenue growth. Another area of concern is the company's significant debt load. CoreWeave exited Q1 with $18.8 billion in total liabilities on its balance sheet, and $8.7 billion of that was debt. To keep up with customer demand for computing power, CoreWeave has to spend on expanding and upgrading AI-optimized hardware, and that's not cheap. As it adds customers, the company must expand its data centers to keep pace. Debt is one way it's funding these capital expenditures. Among the risks of buying its stock, CoreWeave admitted, "Our substantial indebtedness could materially adversely affect our financial condition" and that the company "may still incur substantially more indebtedness in the future." In fact, its Q1 debt total of $8.7 billion was a 10% increase from the prior quarter's $7.9 billion in debt. Seeing an increase in both expenses and debt is a concern, but because CoreWeave is a newly public company, there's not much history to know how well it can manage its finances over the long term. Q1 is the only quarter of financial results it's released since its initial public offering. If subsequent quarters reveal a trend toward getting costs and debt under control while continuing to show strong sales growth, CoreWeave stock may prove to be a worthwhile investment over the long run. But for now, only investors with a high risk tolerance should consider buying shares. Even then, another consideration is CoreWeave's stock valuation. This can be assessed by comparing its price-to-sales (P/S) ratio to other AI companies, such as its customer and fellow cloud provider Microsoft and AI leader Nvidia. CoreWeave's share price surged over recent weeks, causing its P/S multiple to skyrocket past that of Nvidia and Microsoft. The valuation suggests CoreWeave stock is overpriced at this time. Although CoreWeave's sales are strong, given its pricey stock and shaky financials, the ideal approach is to put CoreWeave on your watch list. See how it performs over the next few quarters, and wait for its high valuation to drop before considering an investment. Before you buy stock in CoreWeave, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CoreWeave wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Robert Izquierdo has positions in International Business Machines, Microsoft, and Nvidia. The Motley Fool has positions in and recommends International Business Machines, Microsoft, and Nvidia. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Is CoreWeave Stock a Buy Now? was originally published by The Motley Fool Sign in to access your portfolio
Epoch Times
2 hours ago
- Epoch Times
Nasal, Baby Teething Swabs Recalled Nationwide Over Microbial Contamination Fears
New Jersey-based Church & Dwight Co., Inc. is recalling three nasal and baby teething swab products due to potential fungal contamination in the cotton swab components, the company said in a June 6 The recall is applicable to three products: Zicam Cold Remedy Nasal Swabs designed to tackle the common cold, Zicam Nasal AllClear Swabs used for cleansing, and Orajel Baby Teething Swabs aimed at soothing teething discomfort among toddlers and infants.
